We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Protracted SARS‐CoV‐2 pneumonia with rituximab treatment: About two cases.
- Authors
Gerber, Victor; Velay, Aurélie; Boehn, Louis; Solis, Morgane; Kaeuffer, Charlotte; Rougier, Estelle; Ursenbach, Axel; Hansmann, Yves; Lefebvre, Nicolas; Danion, François; Ruch, Yvon
- Abstract
SARS-CoV-2 infection was confirmed by polymerase chain reaction (PCR) on a nasopharyngeal swab. There is little data on COVID-19 patients previously treated with rituximab.1,2 Here, we present a protracted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with an atypical course in two patients previously treated with rituximab for autoimmune disease. Previously, seven patients treated with anti-CD20 agents with COVID-19 showed inconsistent seroconversion but a favorable outcome.1 Our second observation does not allow us to conclude the effectiveness of convalescent plasma, especially since the patient received remdesivir simultaneously. In SARS-CoV-2 infection, over 90% of immunocompetent patients develop immunoglobulin M and/or IgG within the first 14 days.5-7 Interestingly, IgG anti-SARS-CoV-2 were never positive in our two patients.
- Subjects
NEUROMYELITIS optica; SARS-CoV-2; COVID-19; RITUXIMAB; CONVALESCENT plasma
- Publication
Journal of Medical Virology, 2021, Vol 93, Issue 7, p4141
- ISSN
0146-6615
- Publication type
Article
- DOI
10.1002/jmv.26921